These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 10745488)

  • 41. [Treatment of coronary arteriosclerosis depending on the nature of lipid metabolism disorders].
    Anisimov VE; Semavin IE
    Klin Med (Mosk); 1975 Jul; 53(7):66-9. PubMed ID: 1206996
    [No Abstract]   [Full Text] [Related]  

  • 42. [Lipid-lowering drugs in preventing atherosclerosis].
    Patsch JR
    Internist (Berl); 1989 May; 30(5):309-14. PubMed ID: 2661474
    [No Abstract]   [Full Text] [Related]  

  • 43. [Can we really reach our goals? Arguments for aggressive lipid lowering].
    Internist (Berl); 1999 Sep; 40(9 Suppl Argumente):1-8. PubMed ID: 10528586
    [No Abstract]   [Full Text] [Related]  

  • 44. Hyperlipidemia: treatment with lipid-lowering agents.
    LaRosa JC
    Md Med J; 1988 May; 37(5):401-6. PubMed ID: 3386426
    [No Abstract]   [Full Text] [Related]  

  • 45. [Why does adequate tolerance of a lipid-lowering agent play such an important role?].
    Mutschler E
    Fortschr Med; 1990; 108 Spec No 1():54-5. PubMed ID: 2245962
    [No Abstract]   [Full Text] [Related]  

  • 46. [Hypolipidemic action of simfibrate in diabetic subjects].
    Gragnoli G; Tanganelli I; Signorini AM; Kristodhullu A
    Clin Ter; 1981 Feb; 96(4):397-408. PubMed ID: 7214862
    [No Abstract]   [Full Text] [Related]  

  • 47. [Guidelines for lipid-lowering therapy. Results of the 2d Consensus Conference of the European Atherosclerosis Society. Press conference. London, 6 May 1988].
    Fortschr Med Suppl; 1988; 46():1-22. PubMed ID: 2905324
    [No Abstract]   [Full Text] [Related]  

  • 48. [Indications for surgical treatment and medical treatment of atherosclerosis].
    Paredero Del Bosque Martin V
    Minerva Med; 1980 Oct; 71(40):2963-7. PubMed ID: 7454082
    [No Abstract]   [Full Text] [Related]  

  • 49. [Which lipid class for which lipid disorder?].
    Wasielewski S
    Med Monatsschr Pharm; 2000 Mar; 23(3):94-6. PubMed ID: 10741073
    [No Abstract]   [Full Text] [Related]  

  • 50. [Treatment of hyperlipidemias].
    Culig J
    Lijec Vjesn; 1985; 107(3-4):146-8. PubMed ID: 3982209
    [No Abstract]   [Full Text] [Related]  

  • 51. [Cerivastatine--profile of a new lipid-reducing drug].
    Internist (Berl); 1998 Jan; 39(1 Suppl Cerivastat):1-8. PubMed ID: 9509018
    [No Abstract]   [Full Text] [Related]  

  • 52. [Comparative evaluation of the hypolipidemic effect of cetamiphen, polysponin and miscleron in middle-aged and elderly patients with hypertension].
    Chaialo PP; Tokar' AV; Rudaia ES
    Vrach Delo; 1980 Nov; (11):52-3. PubMed ID: 7467262
    [No Abstract]   [Full Text] [Related]  

  • 53. [Clinical pharmacology of pirozadil].
    Pedraz de Cabo J
    Rev Clin Esp; 1982 Oct; 167(1):15-8. PubMed ID: 7178579
    [No Abstract]   [Full Text] [Related]  

  • 54. Niacin and the National Cholesterol Education Program Adult Treatment Panel III Guidelines: case studies.
    Talbert RL; Pieper JA; Ito MK;
    Am J Health Syst Pharm; 2003 Jul; 60(13 Suppl 2):S22-4; quiz S25. PubMed ID: 12901027
    [No Abstract]   [Full Text] [Related]  

  • 55. Observation of curative effect of lipid lowering and fat restraining tablets on complicated obesity.
    Chen M
    J Tradit Chin Med; 1995 Dec; 15(4):252-5. PubMed ID: 8709602
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Coronary revascularization and aggressive lipid lowering.
    Pershad A; Kratzer S; Cooper A
    J Invasive Cardiol; 1999 Feb; 11(2):87-9. PubMed ID: 10745488
    [No Abstract]   [Full Text] [Related]  

  • 57. [AVERT study (Atorvastatin Versus Revascularization Treatment). Clinical advantage of aggressive lipid lowering].
    Z Kardiol; 1999 Mar; 88(3 Suppl):1-4. PubMed ID: 10330699
    [No Abstract]   [Full Text] [Related]  

  • 58. Statin use in a "real-world" clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial.
    Koren MJ
    Am J Med; 2005 Dec; 118 Suppl 12A():16-21. PubMed ID: 16356803
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aggressive lipid-lowering in stable patients with coronary artery disease.
    Supanich B
    J Fam Pract; 1999 Oct; 48(10):749-50. PubMed ID: 12224668
    [No Abstract]   [Full Text] [Related]  

  • 60. Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease.
    Nordøy A
    Minerva Med; 2002 Oct; 93(5):357-63. PubMed ID: 12410168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.